Melanie_Matheu.jpg

N. Michael Greenberg, PhD

Executive VP of Special Projects

Dr. Greenberg leads internal efforts to develop a therapeutics pipeline in oncology using the Prellis proprietary Externalized Immune System (EXIS™) antibody discovery platform. Dr. Greenberg joins Prellis after 5 years at Atreca, where he was Senior Vice President and Chief Scientific Officer and responsible for research and early development. Dr Greenberg held prior senior leadership roles at Checkmate, AstraZeneca/MedImmune and Pfizer. He has led multi-national teams to discover and develop many important therapies for oncology in the areas of Immuno-Oncology, antibody drug conjugates and bispecific antibodies.

Earlier in his career, Dr. Greenberg held academic appointments as a Full Member in the Clinical Research Division at The Fred Hutchinson Cancer Research Center and as a tenured (Associate) Professor in Cellular and Molecular Biology and Urology at Baylor College of Medicine. He has over 140 patents, publications, awards, and grants to his credit and is highly regarded for his expertise in prostate cancer research. Indeed, Dr. Greenberg generated the first genetically engineered mouse models for prostate cancer including the TRAMP platform which continues to be a critical research platform for discovery and pre-clinical research. Dr. Greenberg received his B.Sc. degree in Microbiology and Immunology from the University of Toronto and his Ph.D. degree in Microbiology and Immunology from the University of British Columbia.